Fushengkang Biotech

Fushengkang Biotech, officially known as Suzhou Fushengkang Biopharmaceutical Co., Ltd., is a clinical-stage biotechnology company and a key subsidiary of the global healthcare group Fosun Pharma. Based in Suzhou, China, the company specializes in the clinical development of innovative small molecule targeted therapies for oncology and rare diseases. Its most advanced candidate, FCN-159, is a highly selective MEK1/2 inhibitor that has received Breakthrough Therapy Designation in China for the treatment of neurofibromatosis type 1 (NF1) and is currently in Phase 3 clinical trials. The company's pipeline also includes FCN-437, a CDK4/6 inhibitor for breast cancer, and several other candidates targeting BCL-2 and BTK. Fushengkang operates as a vital link in Fosun Pharma's R&D ecosystem, translating early-stage discoveries into late-stage clinical assets and eventual commercial products.